Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breakthrough fertility method may keep estrogen low during cancer treatment

NCT ID NCT03947151

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new ovarian stimulation protocol using degarelix (a drug typically used for prostate cancer) to help breast cancer patients preserve their fertility before chemotherapy. The goal was to keep estrogen levels low while still collecting enough eggs for freezing. The study included 8 women aged 18-40 with invasive ductal breast cancer who needed chemotherapy. Researchers measured how many follicles (egg sacs) developed and whether estrogen stayed at safe levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

8 people

The number who actually took part.

Started

Nov 2019

Finished

Aug 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with invasive ductal carcinoma breast cancer, whatever the hormonal receptor expression profile * Age : 18 - 40 years * Presence of 2 ovaries * Antral follicular count between 12 and 30 on both ovaries and/or recent measurement of serum anti-Müllerian hormone between 1.5 and 4 ng / mL (between Day-25 and Day0) * Indication of chemotherapy * Indication of preservation of fertility according to an oocyte vitrification technique after controlled ovarian stimulation (COS) * Patient in the early follicular phase of the cycle at the start of the controlled ovarian stimulation (COS) (absence of follicle\> 10 mm in ultrasound and estradiolemia \<50 pg / mL) * Oncology team agreement for the controlled ovarian stimulation (COS) * Social insured patient * Patient who gave her consent to participate by signing the consent of the study Exclusion Criteria: * Patient in late follicular phase or luteal phase * Known hypersensitivity to one of the constituents of Firmagon®

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Invasive ductal breast carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast ductal adenocarcinoma invasive ductal breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Invasive ductal breast carcinoma

Contacts and locations

Locations

  • Hôpital Antoine Béclère

    Clamart, 92140, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.